Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-132P is a pseudogene copy of the gene encoding U6 small nuclear RNA, which itself is a non-coding RNA essential for the spliceosome’s function in pre-mRNA splicing[3][5]. Pseudogenes are faulty gene copies created during genome evolution—RNU6-132P contains sequence similarities to U6 snRNA but is assumed not to be transcribed or functional, and there is no evidence it produces RNA or protein[1][6]. The existence of multiple U6 pseudogenes in the genome is common and reflects the evolutionary significance of the original U6 snRNA gene, but these copies are generally inert[3][5]. There are no well-documented disease associations, biological functions, or known drug interactions for RNU6-132P. It is not considered a receptor, enzyme, transporter, or transcription factor, and should not be treated as a canonical therapeutic target or biomarker[1][6]. If you require a curated molecular target, refer to the functional U6 snRNA gene (not its pseudogene derivatives), or other canonical drug targets.
None (no drugs target RNU6-132P)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 132, pseudogene (RNU6-132P).